News

  • 05/16/2013 Medigene publishes final results from phase II Investigator Initiated Trial of EndoTAG®-1 at ASCO 2013 more…
  • 05/14/2013 Medigene reports financial results for the first quarter of 2013 more…

Webcast

Webcast to Press and Analyst Conference Call

regarding the publication of the 3-Month Report 2013 May 14th, 2013 at 11:00 am CEST.

  • One 2
  • 1+1
  • 5+1

Products / Pipeline

Research Clinical Development Market

Eligard®

In June 2012, Medigene transferred ist 2% royalty share on Eligard® net sales to Cowen Royalty for a cash payment of appr. €14.1 million.

Further information …

Veregen®

Medigene is responsible for the clinical development of Veregen®, for which it obtained approval, and which is used in the treatment of genital warts. The ointment is marketed globally by business partners.

Further information …

EndoTAG®-1

Medigene has successfully completed two Phase II clinical trials for EndoTAG®-1, a drug candidate for the treatment of pancreatic cancer and triple-negative breast cancer.

Further information …

RhuDex®

Medigene is developing RhuDex® for the treatment of auto-immune diseases, such as rheumatoid arthritis.

Further information …

AAVLP

Medigene is currently conducting research into the application of AAVLP technology for the treatment of cancer and viral infections, and is examining the possibility of using AAV libraries to systematically identify suitable vaccine candidates.

Further information …
For more information on our products, just move your mouse over the bars.

Conference

  • 05/22/2013 – 05/23/2013 // Stockholm BioEquity Europe
  • 06/03/2013 – 06/06/2013 // New York Jefferies 2013 Global Healthcare Conference
More
Llewellyn-Davies

„Our company’s financial results and operational development in the first months 2013 are in line with our expectations and demonstrate a positive trend.“Peter Llewellyn-Davies, CFO